Royalty Pharma plc (RPRX) Stock

About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc is led by CEO Pablo Legorreta, employs 75 people, headquartered in New York, US, publicly traded since 2020.

Royalty Pharma plc (RPRX) stock trades at $59.79 with a market capitalization of $25.72B. The stock is valued at a price-to-earnings (P/E) ratio of 27.21, price-to-book of 3.42, price-to-sales of 9.27. Over the past 52 weeks the stock has ranged between $32.15 and $59.79, and currently trades at its 52-week high. It pays a dividend yielding 1.73%.

On profitability, Royalty Pharma plc generates a return on equity (ROE) of 13.77%, above the typical market average, return on capital employed of 16.06%, an operating margin of 1.00%, a net profit margin of 33.91%.

In its most recent fiscal year, Royalty Pharma plc reported annual revenue of $2.4B, net profit of $771.0M, revenue has compounded at 2.3% a year over the last five years, profit at -4.6% a year.

The balance sheet shows a debt-to-equity ratio of 1.30, a current ratio of 2.66, total assets of $19.6B, $619.0M in cash and equivalents.

RPRX has an average daily trading volume of 3,656,619 shares, a beta of 0.42 (less volatile than the overall market).

Official website: www.royaltypharma.com